Viemed Healthcare to Present at Stifel 2023 Healthcare Conference

Viemed Healthcare, Inc. (the " Company " or " Viemed ") (NASDAQ:VMD and TSX:VMD.TO), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it will participate in the Stifel 2023 Healthcare Conference on November 15, 2023, in New York, New York at the Lotte New York Palace Hotel, located at 455 Madison Ave.

Casey Hoyt, CEO, and Todd Zehnder, COO, will conduct a presentation that will cover key areas of Viemed's business at 1:15pm EST. Additionally, investors that are registered for the conference will have the ability to request one-on-one meetings with management.

The presentation webcast and presentation slides will be available live and can be accessed through the following link:

https://wsw.com/webcast/stifel83/vmd.to/2368752

Following the event, a replay of the presentation will remain available for 90 days.

ABOUT Viemed Healthcare, INC.

Viemed is a provider of in-home medical equipment and post-acute respiratory healthcare services in the United States. Viemed's service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counseling to patients in their homes using cutting-edge technology. Visit our website at www.viemed.com.

For further information, please contact:

Glen Axelrod
Bristol Capital
905-326-1888
glen@bristolir.com

Todd Zehnder
Chief Operating Officer
Viemed Healthcare, Inc.
337-504-3802
investorinfo@viemed.com

News Provided by GlobeNewswire via QuoteMedia

viemed healthcare vmd nasdaq:vmd life science investing Life Science Investing

VMD

Viemed Healthcare Announces Record Third Quarter 2023 Financial Results

Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD and TSX:VMD.TO), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it has reported its financial results for the three and nine months ended September 30, 2023.

Operational highlights (all dollar amounts are USD):

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Viemed Announces Successful Completion Of HMP Acquisition

Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD and TSX:VMD.TO), a national leader in respiratory care and technology-enabled home medical equipment services, announced that it has successfully completed its previously announced acquisition of Tennessee based Home Medical Products, Inc. ("HMP"), a large regional provider of respiratory focused home medical solutions.

"I'm incredibly proud to welcome the HMP team to the Viemed family. Both organizations share a culture that focuses on high quality patient interaction in the home driven by clinical excellence and supported by technology," said Viemed Chief Executive Officer Casey Hoyt. "Today, we immediately expand our existing reach through product, payor, and geographic diversity. We will continue our on-going efforts to ensure a seamless integration of the two organizations and to leverage our shared experience to deliver synergized growth while driving positive clinical outcomes and improving the quality of life for our patients."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Ocumetics Continues to Meet Significant Development Milestones; Lens Design Optimized for Upcoming First in Human Study

(TheNewswire)

Calgary, Alberta September 18, 2023. Ocumetics Technology Corp. (" Ocumetics ") ( TSXV:OTC) (OTC:OTCFF) (FRA:2QBO), a pioneer in in the field of ophthalmic innovation, proudly confirms a remarkable achievement in the optimization of its vision correction technology - the Ocumetics Accommodating Lens. Through rigorous research and development efforts over the past two years, Ocumetics has modified its lens design five times, ultimately arriving at its groundbreaking final lens configuration version 10.5. Lens version 10.5 has been tested in vitro and in an animal model, and will be used in Ocumetics' upcoming human clinical trials.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less

Sona's 'THT' Cancer Therapy to be Assessed for Efficacy and Ability to Act as a Catalyst to Generate Immune Responses in Research Study

Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce an innovative research initiative to be undertaken with The Giacomantonio Immuno-Oncology Research Group (the "Research Group"). This study aims to evaluate the efficacy of Sona's Targeted Hyperthermia Therapy ("THT") technology in not only attenuating the development of colorectal, breast, and melanoma tumor models in mice but also in facilitating systemic immune responses.

The study posits that the combined utilization of Sona's gold nanorods via its Targeted Hyperthermia Therapy, alongside precise immune modulation, will result in elevated immune activation and anti-tumor responses within the mouse models of colorectal cancer, breast cancer, and melanoma.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Viemed Healthcare, INC. CONDENSED CONSOLIDATED BALANCE SHEETS *(Expressed in thousands of U.S. Dollars, except share amounts)* *(Unaudited)*

	At September 30, 2023		At December 31, 2022
ASSETS
Current assets
Cash and cash equivalents	$	10,078	$	16,914
Accounts receivable, net		17,926		15,379
Inventory		4,670		3,574
Income tax receivable		—		26
Prepaid expenses and other assets		3,187		3,849
Total current assets	$	35,861	$	39,742
Long-term assets
Property and equipment, net		73,423		67,743
Finance lease right-of-use assets		531		—
Operating lease right-of-use assets		461		694
Equity investments		1,771		2,155
Debt investment		2,164		2,000
Deferred tax asset		3,910		3,119
Identifiable intangibles, net		688		—
Goodwill		29,704		—
Other long-term assets		887		1,590
Total long-term assets	$	113,539	$	77,301
TOTAL ASSETS	$	149,400	$	117,043
LIABILITIES
Current liabilities
Trade payables	$	5,978	$	2,650
Deferred revenue		6,215		4,624
Income taxes payable		232		—
Accrued liabilities		16,719		11,092
Finance lease liabilities, current portion		333		—
Operating lease liabilities, current portion		242		495
Current debt		1,834		—
Total current liabilities	$	31,553	$	18,861
Long-term liabilities
Accrued liabilities		543		889
Finance lease liabilities, less current portion		180		—
Operating lease liabilities, less current portion		215		199
Long-term debt		8,095		—
Total long-term liabilities	$	9,033	$	1,088
TOTAL LIABILITIES	$	40,586	$	19,949
Commitments and Contingencies		—		—
SHAREHOLDERS' EQUITY
Common stock - No par value: unlimited authorized; 38,489,001 and 38,049,739 issued and outstanding as of September 30, 2023 and December 31, 2022, respectively		18,633		15,123
Additional paid-in capital		14,164		12,125
Retained earnings		76,017		69,846
TOTAL SHAREHOLDERS' EQUITY	$	108,814	$	97,094
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$	149,400	$	117,043

Viemed Healthcare, INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME *(Expressed in thousands of U.S. Dollars, except outstanding shares and per share amounts)* *(Unaudited)*

	Three Months Ended September 30,						Nine Months Ended September 30,
		2023			2022			2023			2022
Revenue	$	49,402		$	35,759		$	132,269		$	101,324

Cost of revenue		18,840			14,108			51,597			39,540

Gross profit	$	30,562		$	21,651		$	80,672		$	61,784

Operating expenses
Selling, general and administrative		23,654			17,677			63,979			50,989
Research and development		593			670			2,131			1,974
Stock-based compensation		1,453			1,309			4,315			3,885
Depreciation		419			291			957			771
Loss on disposal of property and equipment		278			292			373			168
Other (income) expense, net		(41	)		(57	)		(124	)		(721	)
Income from operations	$	4,206		$	1,469		$	9,041		$	4,718

Non-operating income and expenses
Income from equity method investments		270			84			442			853
Interest expense, net		(237	)		(42	)		(168	)		(165	)

Net income before taxes		4,239			1,511			9,315			5,406
Provision for income taxes		1,320			456			2,549			1,622

Net income	$	2,919		$	1,055		$	6,766		$	3,784

Other comprehensive income (loss)
Change in unrealized gain/loss on derivative instruments, net of tax		—			112			—			334
Other comprehensive income (loss)	$	—		$	112		$	—		$	334

Comprehensive income	$	2,919		$	1,167		$	6,766		$	4,118

Net income per share
Basic	$	0.08		$	0.03		$	0.18		$	0.10
Diluted	$	0.07		$	0.03		$	0.17		$	0.09

Weighted average number of common shares outstanding:
Basic		38,438,058			38,232,788			38,307,343			38,870,949
Diluted		40,420,615			39,583,438			40,391,729			39,852,297

Viemed Healthcare, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Expressed in thousands of U.S. Dollars) (Unaudited)
	Nine Months Ended September 30,
		2023			2022
Cash flows from operating activities
Net income	$	6,766		$	3,784
Adjustments for:
Depreciation		15,943			11,257
Change in inventory reserve		—			(1,418	)
Stock-based compensation expense		4,315			3,885
Distributions of earnings received from equity method investments		833			931
Income from equity method investments		(442	)		(853	)
Income from debt investment		(164	)		—
Loss on disposal of property and equipment		373			168
Deferred income tax (benefit) expense		(791	)		745
Changes in working capital, net of effects from acquisitions:
Accounts receivable, net		(533	)		(2,159	)
Inventory		(514	)		697
Prepaid expenses and other assets		1,193			(2,870	)
Trade payables		(255	)		33
Deferred revenue		859			892
Accrued liabilities		4,086			3,170
Income tax payable/receivable		259			1,802
Net cash provided by operating activities	$	31,928		$	20,064
Cash flows from investing activities
Purchase of property and equipment		(18,161	)		(17,326	)
Investment in equity investments		(7	)		(141	)
Cash paid for acquisition of HMP, net of cash acquired		(28,580	)		—
Proceeds from sale of property and equipment		2,128			869
Net cash used in investing activities	$	(44,620	)	$	(16,598	)
Cash flows from financing activities
Proceeds from exercise of options		1,234			87
Proceeds from term notes		5,000			—
Principal payments on term notes		(2,746	)		(1,440	)
Proceeds from revolving credit facilities		8,000			—
Payments on revolving credit facilities		(5,005	)		—
Shares redeemed to pay income tax		(595	)		(143	)
Shares repurchased under the share repurchase program		—			(8,858	)
Repayments of lease liabilities		(32	)		(42	)
Net cash provided by (used in) financing activities	$	5,856		$	(10,396	)
Net decrease in cash and cash equivalents		(6,836	)		(6,930	)
Cash and cash equivalents at beginning of year		16,914			28,408
Cash and cash equivalents at end of period	$	10,078		$	21,478

Supplemental disclosures of cash flow information
Cash paid during the period for interest	$	497		$	185
Cash paid (received) during the period for income taxes, net of refunds	$	3,218		$	(920	)

Viemed Healthcare, INC. Reconciliation of Net Income to Non-GAAP Adjusted EBITDA *(Expressed in thousands of U.S. Dollars)* *(Unaudited)*

For the quarter ended	September 30, 2023		June 30, 2023			March 31, 2023			December 31, 2022		September 30, 2022		June 30, 2022		March 31, 2022		December 31, 2021
Net Income	$	2,919	$	2,330		$	1,517		$	2,438	$	1,055	$	967	$	1,762	$	4,087
Add back:
Depreciation		5,975		5,207			4,762			4,373		4,120		3,740		3,397		3,120
Interest expense (income)		237		(20	)		(49	)		32		42		59		64		69
Stock-based compensation ^(a)		1,453		1,471			1,391			1,317		1,309		1,271		1,305		1,305
Transaction costs ^(b)		177		94			206			—		—		—		—		—
Income tax expense		1,320		728			501			1,146		456		421		745		968
Adjusted EBITDA	$	12,081	$	9,810		$	8,328		$	9,306	$	6,982	$	6,458	$	7,273	$	9,549


	Three Months Ended September 30, 2023		Nine Months Ended September 30, 2023
Net Income	$	2,919	$	6,766
Add back:
Depreciation		5,975		15,944
Interest expense		237		168
Stock-based compensation ^(a)		1,453		4,315
Transaction costs ^(b)		177		477
Income tax expense (benefit)		1,320		2,549
Adjusted EBITDA	$	12,081	$	30,219

Viemed Healthcare, INC. Key Financial and Operational Information *(Expressed in thousands of U.S. Dollars, except vent patients)* *(Unaudited)*

For the quarter ended	September 30, 2023			June 30, 2023			March 31, 2023			December 31, 2022			September 30, 2022			June 30, 2022			March 31, 2022			December 31, 2021
Financial Information:
Revenue	$	49,402		$	43,311		$	39,556		$	37,508		$	35,759		$	33,310		$	32,255		$	31,962
Gross Profit	$	30,562		$	26,106		$	24,004		$	22,896		$	21,651		$	20,390		$	19,743		$	19,662
Gross Profit %		62	%		60	%		61	%		61	%		61	%		61	%		61	%		62	%
Net Income	$	2,919		$	2,330		$	1,517		$	2,438		$	1,055		$	967		$	1,762		$	4,087
Cash (As of)	$	10,078		$	10,224		$	23,544		$	16,914		$	21,478		$	21,922		$	29,248		$	28,408
Total Assets (As of)	$	149,400		$	149,117		$	124,634		$	117,043		$	119,419		$	115,904		$	119,007		$	117,962
Adjusted EBITDA ⁽¹⁾	$	12,081		$	9,810		$	8,328		$	9,306		$	6,982		$	6,458		$	7,273		$	9,549
Operational Information:
Vent Patients ⁽²⁾		10,244			10,005			9,337			9,306			9,127			8,837			8,434			8,405

Viemed Healthcare, INC. CONDENSED CONSOLIDATED BALANCE SHEETS *(Expressed in thousands of U.S. Dollars, except share amounts)* *(Unaudited)*

	At June 30, 2023		At December 31, 2022
ASSETS
Current assets
Cash and cash equivalents	$	10,224	$	16,914
Accounts receivable, net		17,893		15,379
Inventory		4,476		3,574
Income tax receivable		1,029		26
Prepaid expenses and other assets		2,327		3,849
Total current assets	$	35,949	$	39,742
Long-term assets
Property and equipment, net		72,884		67,743
Finance lease right-of-use assets		538		—
Operating lease right-of-use assets		516		694
Equity investments		1,942		2,155
Debt investment		2,110		2,000
Deferred tax asset		3,844		3,119
Identifiable intangibles, net		688		—
Goodwill		29,759		—
Other long-term assets		887		1,590
Total long-term assets	$	113,168	$	77,301
TOTAL ASSETS	$	149,117	$	117,043

LIABILITIES
Current liabilities
Trade payables	$	6,167	$	2,650
Deferred revenue		5,960		4,624
Accrued liabilities		15,509		11,092
Finance lease liabilities, current portion		375		—
Operating lease liabilities, current portion		395		495
Current debt		3,169		—
Total current liabilities	$	31,575	$	18,861
Long-term liabilities
Accrued liabilities		637		889
Finance lease liabilities, less current portion		143		—
Operating lease liabilities, less current portion		143		199
Long-term debt		12,114		—
Total long-term liabilities	$	13,037	$	1,088
TOTAL LIABILITIES	$	44,612	$	19,949

Commitments and Contingencies		—		—

SHAREHOLDERS' EQUITY
Common stock - No par value: unlimited authorized; 38,400,422 and 38,049,739 issued and outstanding as of June 30, 2023 and December 31, 2022, respectively		17,850		15,123
Additional paid-in capital		13,488		12,125
Retained earnings		73,167		69,846
TOTAL SHAREHOLDERS' EQUITY	$	104,505	$	97,094
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$	149,117	$	117,043

Viemed Healthcare, INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME *(Expressed in thousands of U.S. Dollars, except outstanding shares and per share amounts)* *(Unaudited)*

	Three Months Ended June 30,						Six Months Ended June 30,
	2023			2022			2023			2022
Revenue	$	43,311		$	33,310		$	82,867		$	65,565

Cost of revenue		17,205			12,920			32,757			25,432

Gross profit	$	26,106		$	20,390		$	50,110		$	40,133

Operating expenses
Selling, general and administrative		20,563			17,536			40,325			33,312
Research and development		758			672			1,538			1,304
Stock-based compensation		1,471			1,271			2,862			2,576
Depreciation		298			243			538			480
Loss (gain) on disposal of property and equipment		117			(110	)		95			(124	)
Other (income) expense, net		(2	)		(223	)		(83	)		(664	)
Income from operations	$	2,901		$	1,001		$	4,835		$	3,249

Non-operating income and expenses
Income from equity method investments		137			446			172			769
Interest income (expense), net		20			(59	)		69			(123	)

Net income before taxes		3,058			1,388			5,076			3,895
Provision for income taxes		728			421			1,229			1,166

Net income	$	2,330		$	967		$	3,847		$	2,729

Other comprehensive income (loss)
Change in unrealized gain/loss on derivative instruments, net of tax		—			59			—			222
Other comprehensive income (loss)	$	—		$	59		$	—		$	222

Comprehensive income	$	2,330		$	1,026		$	3,847		$	2,951

Net income per share
Basic	$	0.06		$	0.02		$	0.10		$	0.07
Diluted	$	0.06		$	0.02		$	0.10		$	0.07

Weighted average number of common shares outstanding:
Basic		38,324,249			38,773,580			38,240,902			39,195,317
Diluted		40,676,951			39,752,928			40,383,616			40,056,953

Viemed Healthcare, INC. Reconciliation of Net Income to Non-GAAP Adjusted EBITDA *(Expressed in thousands of U.S. Dollars)* *(Unaudited)*

For the quarter ended	June 30, 2023			March 31, 2023			December 31, 2022		September 30, 2022		June 30, 2022		March 31, 2022		December 31, 2021		September 30, 2021
Net Income	$	2,330		$	1,517		$	2,438	$	1,055	$	967	$	1,762	$	4,087	$	1,789
Add back:
Depreciation		5,207			4,762			4,373		4,120		3,740		3,397		3,120		2,867
Interest expense (income)		(20	)		(49	)		32		42		59		64		69		75
Stock-based compensation ^(a)		1,471			1,391			1,317		1,309		1,271		1,305		1,305		1,302
Transaction costs ^(b)		94			206			—		—		—		—		—		—
Income tax expense		728			501			1,146		456		421		745		968		1,386
Adjusted EBITDA	$	9,810		$	8,328		$	9,306	$	6,982	$	6,458	$	7,273	$	9,549	$	7,419


	Three Months Ended June 30, 2023			Six Months Ended June 30, 2023
Net Income	$	2,330		$	3,847
Add back:
Depreciation		5,207			9,969
Interest expense		(20	)		(69	)
Stock-based compensation ^(a)		1,471			2,862
Transaction costs ^(b)		94			300
Income tax expense (benefit)		728			1,229
Adjusted EBITDA	$	9,810		$	18,138

Viemed Healthcare, INC. Key Financial and Operational Information *(Expressed in thousands of U.S. Dollars, except vent patients)* *(Unaudited)*

For the quarter ended	June 30, 2023			March 31, 2023			December 31, 2022			September 30, 2022			June 30, 2022			March 31, 2022			December 31, 2021			September 30, 2021
Financial Information:
Revenue	$	43,311		$	39,556		$	37,508		$	35,759		$	33,310		$	32,255		$	31,962		$	29,285
Gross Profit	$	26,106		$	24,004		$	22,896		$	21,651		$	20,390		$	19,743		$	19,662		$	18,381
Gross Profit %		60	%		61	%		61	%		61	%		61	%		61	%		62	%		63	%
Net Income	$	2,330		$	1,517		$	2,438		$	1,055		$	967		$	1,762		$	4,087		$	1,789
Cash (As of)	$	10,224		$	23,544		$	16,914		$	21,478		$	21,922		$	29,248		$	28,408		$	26,867
Total Assets (As of)	$	149,117		$	124,634		$	117,043		$	119,419		$	115,904		$	119,007		$	117,962		$	115,486
Adjusted EBITDA ⁽¹⁾	$	9,810		$	8,328		$	9,306		$	6,982		$	6,458		$	7,273		$	9,549		$	7,419
Operational Information:
Vent Patients ⁽²⁾		10,005			9,337			9,306			9,127			8,837			8,434			8,405			8,200


Viemed Healthcare, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
*(Expressed in thousands of U.S. Dollars, except share amounts)*
(Unaudited)

	At March 31, 2023		At December 31, 2022
ASSETS
Current assets
Cash and cash equivalents	$	23,544	$	16,914
Accounts receivable, net of allowance for doubtful accounts of $11,040 and $8,483 at March 31, 2023 and December 31, 2022, respectively		16,320		15,379
Inventory		3,447		3,574
Income tax receivable		—		26
Prepaid expenses and other assets		3,394		3,849
Total current assets	$	46,705	$	39,742
Long-term assets
Property and equipment, net		68,438		68,437
Equity investments		1,994		2,155
Debt investment		2,057		2,000
Deferred tax asset		3,844		3,119
Other long-term assets		1,596		1,590
Total long-term assets	$	77,929	$	77,301
TOTAL ASSETS	$	124,634	$	117,043

LIABILITIES
Current liabilities
Trade payables	$	4,262	$	2,650
Deferred revenue		4,698		4,624
Income taxes payable		1,247		—
Accrued liabilities		12,817		11,092
Current portion of lease liabilities		397		495
Total current liabilities	$	23,421	$	18,861
Long-term liabilities
Accrued liabilities		1,010		889
Long-term lease liabilities		162		199
Total long-term liabilities	$	1,172	$	1,088
TOTAL LIABILITIES	$	24,593	$	19,949

Commitments and Contingencies		—		—

SHAREHOLDERS' EQUITY
Common stock - No par value: unlimited authorized; 38,276,389 and 38,049,739 issued and outstanding as of March 31, 2023 and December 31, 2022, respectively		17,096		15,123
Additional paid-in capital		12,087		12,125
Retained earnings		70,858		69,846
TOTAL SHAREHOLDERS' EQUITY	$	100,041	$	97,094

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$	124,634	$	117,043

Viemed Healthcare, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME
(Expressed in thousands of U.S. Dollars, except outstanding shares and per share amounts)
(Unaudited)


	Three Months Ended March 31,
		2023			2022
Revenue	$	39,556		$	32,255

Cost of revenue		15,552			12,512

Gross profit	$	24,004		$	19,743

Operating expenses
Selling, general and administrative		19,762			15,776
Research and development		780			632
Stock-based compensation		1,391			1,305
Depreciation		240			237
Gain on disposal of property and equipment		(22	)		(14	)
Other (income) expense, net		(81	)		(441	)
Income from operations	$	1,934		$	2,248

Non-operating income and expenses
Income from equity method investments		(35	)		(323	)
Interest (income) expense, net		(49	)		64

Net income before taxes		2,018			2,507
Provision for income taxes		501			745

Net income	$	1,517		$	1,762

Other comprehensive income
Change in unrealized gain/loss on derivative instruments, net of tax		—			163
Other comprehensive income	$	—		$	163

Comprehensive income	$	1,517		$	1,925

Net income per share
Basic	$	0.04		$	0.04
Diluted	$	0.04		$	0.04

Weighted average number of common shares outstanding:
Basic		38,156,777			39,621,741
Diluted		40,016,693			40,363,456

Viemed Healthcare, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Expressed in thousands of U.S. Dollars)
(Unaudited)

	Three Months Ended March 31,
		2023			2022
Cash flows from operating activities
Net income	$	1,517		$	1,762
Adjustments for:
Depreciation		4,762			3,397
Provision for uncollectible accounts		4,131			3,445
Change in inventory reserve		—			(1,418	)
Stock-based compensation expense		1,391			1,305
Distributions of earnings received from equity method investments		196			221
Income from equity method investments		(35	)		(323	)
Income from debt investment		(57	)		—
Gain on disposal of property and equipment		(22	)		(14	)
Deferred income tax (benefit) expense		(725	)		745
Net change in working capital
Increase in accounts receivable		(5,072	)		(4,221	)
Decrease in inventory		127			1,372
Decrease (increase) in prepaid expenses and other assets		449			(68	)
Increase (decrease) in trade payables		641			(467	)
Increase in deferred revenue		74			135
Increase in accrued liabilities		1,846			58
Change in income tax payable/receivable		1,273			1,217
Net cash provided by operating activities	$	10,496		$	7,146

Cash flows from investing activities
Purchase of property and equipment		(4,681	)		(3,963	)
Investment in equity investments		—			(100	)
Proceeds from sale of property and equipment		776			256
Net cash used in investing activities	$	(3,905	)	$	(3,807	)

Cash flows from financing activities
Proceeds from exercise of options		544			—
Principal payments on notes payable		—			(39	)
Principal payments on term note		—			(433	)
Shares repurchased under the share repurchase program		—			(1,887	)
Shares redeemed to pay income tax		(505	)		(119	)
Repayments of lease liabilities		—			(21	)
Net cash provided by (used in) financing activities	$	39		$	(2,499	)

Net increase in cash and cash equivalents		6,630			840
Cash and cash equivalents at beginning of year		16,914			28,408
Cash and cash equivalents at end of period	$	23,544		$	29,248

Supplemental disclosures of cash flow information
Cash paid during the period for interest	$	42		$	66
Cash (received) paid during the period for income taxes, net of refunds	$	(40	)	$	1,217

Viemed Healthcare, INC.
Reconciliation of Net Income to Non-GAAP Adjusted EBITDA
(Expressed in thousands of U.S. Dollars)
(Unaudited)

For the quarter ended	March 31, 2023			December 31, 2022		September 30, 2022		June 30, 2022		March 31, 2022		December 31, 2021		September 30, 2021		June 30, 2021
Net Income	$	1,517		$	2,438	$	1,055	$	967	$	1,762	$	4,087	$	1,789	$	1,566
Add back:
Depreciation		4,762			4,373		4,120		3,740		3,397		3,120		2,867		2,716
Interest (income) expense		(49	)		32		42		59		64		69		75		83
Stock-based compensation ^(a)		1,391			1,317		1,309		1,271		1,305		1,305		1,302		1,236
Transaction costs ^(b)		206			—		—		—		—		—		—		—
Income tax expense		501			1,146		456		421		745		968		1,386		1,246
Adjusted EBITDA	$	8,328		$	9,306	$	6,982	$	6,458	$	7,273	$	9,549	$	7,419	$	6,847

Viemed Healthcare, INC.
Key Financial and Operational Information
(Expressed in thousands of U.S. Dollars, except vent patients)
(Unaudited)

For the quarter ended	March 31, 2023			December 31, 2022			September 30, 2022			June 30, 2022			March 31, 2022			December 31, 2021			September 30, 2021			June 30, 2021
Financial Information:
Revenue	$	39,556		$	37,508		$	35,759		$	33,310		$	32,255		$	31,962		$	29,285		$	27,399
Gross Profit	$	24,004		$	22,896		$	21,651		$	20,390		$	19,743		$	19,662		$	18,381		$	17,625
Gross Profit %		61	%		61	%		61	%		61	%		61	%		62	%		63	%		64	%
Net Income	$	1,517		$	2,438		$	1,055		$	967		$	1,762		$	4,087		$	1,789		$	1,566
Cash (As of)	$	23,544		$	16,914		$	21,478		$	21,922		$	29,248		$	28,408		$	26,867		$	31,151
Total Assets (As of)	$	124,634		$	117,043		$	119,419		$	115,904		$	119,007		$	117,962		$	115,486		$	111,014
Adjusted EBITDA ⁽¹⁾	$	8,328		$	9,306		$	6,982		$	6,458		$	7,273		$	9,549		$	7,419		$	6,847
Operational Information:
Vent Patients ⁽²⁾		9,337			9,306			9,127			8,837			8,434			8,405			8,200			8,103

Viemed Healthcare to Present at Stifel 2023 Healthcare Conference

Latest Press Releases

Related News

TOP STOCKS